In Crohn's disease neutrophils accumulate abnormally slowly at a site of acute inflammation,' a defect which may be related to the pathogenesis of the disease. Levamisole is thought to stimulate defective immunity non-specifically, and, in particular, to stimulate neutrophil migration.2 We performed a study to determine whether levamisole could maintain patients with Crohn's disease in remission after this had been induced by treatment with an elemental diet. Two of the eight patients managed in this way developed a severe arthritis which was closely associated with levamisole administration and subsided after withdrawal of the drug.
Case 1
A 22-year-old man developed diarrhoea, colicky abdominal pain, and weight loss in May 1976. He had noticed occasional aching in his left elbow and knee. There was no swelling or limitation of movements in these joints and no radiological abnormality. He was feverish and his spleen was enlarged 2 cm below the costal margin. Barium studies showed mucosal ulceration of the terminal ileum and caecum and stenosis of the affected ileum. An infective cause for these lesions was not found and Crohn's disease was diagnosed, the only atypical feature being selective IgA deficiency (IgA 0 13 g/l, IgG 15-1 g,l1, IgM 1 4 g/l). He was given an elemental diet for a month, and after the first two weeks he received levamisole 150 mg/day for three consecutive days every two weeks. Clinical remission was induced within a few days of starting the elemental diet.
Five months after starting levamisole treatment side effects were observed. Crohn's disease was diagnosed on the basis of the barium enema examination, which showed extensive ulceration of the colon from the caecum to the sigmoid colon, and rectal biopsy, which showed a histiocytic granuloma. She initially responded to bowel sterilisation6 but later relapsed and was treated with the same regimen as the first patient. Before starting levamisole treatment she had occasional stiffness in the hands and back, but there was no swelling of the joints and no radiological abnormality.
Three months after starting levamisole she developed generalised arthritis on three successive courses of treatment. In each case the arthritis had an identical pattern but it increased in severity with each course. Twelve hours after the first dose she noticed the gradual onset of generalised pain in the joints. This was particularly severe in her hands, which became swollen; cervical spine; and temporomandibular joints. On the third occasion these symptoms were so severe that she could not eat, grasp objects, or walk. Symptoms resolved spontaneously 24-48 hours after stopping the drug and did not recur after withdrawal of treatment. There were no residual symptoms or signs of joint damage. Three months after stopping treatment precipitating antibodies to the drug were not shown in serum, and blast transformation of lymphocytes did not occur.
Comment
Two of the eight patients with Crohn's disease whom we have treated with levamisole developed severe arthritis. Both these patients had had mild arthralgia, with a distribution similar to that of the arthritis associated with drug administration. The absence of reports of levamisole-induced arthritis, despite the drug's wide use for various conditions, including malignant and rheumatic diseases, sarcoidosis, and viral skin disease,7 suggests that this complication is specifically related to Crohn's disease. There was no evidence that immune complex formation or complement activation were concerned, and precipitating antibodies to or lymphocyte activation by levamisole were not detected with the methods used. It seems likely that the drug induced an arthritis, an accepted complication of Crohn's disease,8 in these patients by unmasking latent mechanisms of joint damage.
Elucidation of the mechanisms of action of levamisole should give valuable insight into the pathogenesis of the arthritis associated with Crohn's disease and possibly arthritis in general. 
Levamisole-induced thrombocytopenia
Levamisole (L-tetramisole) is an anthelmintic drug with immunostimulating capacity in certain immunodeficiency states,' which has been reported to have beneficial effects in rheumatoid arthritis.' We are currently assessing the drug in adults with rheumatoid arthritis, and we report here a patient with rheumatoid arthritis who developed thrombocytopenia while taking levamisole.
Case report
A 59-year-old woman was first seen at the outpatient department on 7 October 1976 with a six-month history of polyarthritis. The Ritchie articular index of joint tenderness3 was + 19. There were no subcutaneous nodules and no hepatosplenomegaly. The rheumatoid factor test (R3 test) was strongly positive at a titre of 1/512 and the antinuclear factor titre was 1/16 (homogenous-pattern). Joint radiographs showed erosive changes in the hands and feet. Other laboratory investigations showed: haemoglobin 11-2 g/dl, total white cell count 8-2 x 109/1, platelets 177 x 109/1, and erythrocyte sedimentation rate 44 mm in the first hour. Other biochemical values were normal. A chest radiograph showed nothing abnormal.
The patient was treated with indomethacin 200 mg/day and oral iron. Despite the large dose of indomethacin she continued to suffer severe joint pain, and feprazone (pyrazolidinedione derivative; Meprazone; Boehringer Ingelheim Ltd) 600 mg/day was started on 25 November. Because she failed to respond to feprazone, the patient was started on levamisole on 7 January 1977 -in a daily dose of 150 mg. Naproxen 750 mg/day was also begun and feprazone discontinued. On 11 February the platelet count was reduced at 31 x 109/1. Levamisole was immediately discontinued and a week later the platelet count had returned to normal (150 x 109/1). Levamisole was restarted in a dose of 100 mg/day. On 21 March 1977 the platelet count had again fallen to 87 x 109/1. The haemoglobin concentration was 13-3 g/dl and the total white cell count 57 x 109/1. Levamisole was discontinued and on 14 April 1977 the platelet count was again normal (159 x 109!1).
Comment
Although agranulocytosis has been reported in patients with rheumatoid arthritis taking levamisole,4 we can find no report of thrombocytopenia caused by levamisole therapy. Our patient was receiving only naproxen and levamisole when thrombocytopenia developed. The platelet count quickly returned to normal on stopping levamisole despite the fact that naproxen was continued. When levamisole was reintroduced in a smaller dose thrombocytopenia again resulted, and the platelet count again quickly returned to normal on stopping the drug. Levamisole was therefore almost certainly the agent responsible for the thrombocytopenia. We did not consider it justified to carry out bone marrow examination, especially as the patient was rather nervous at the thought of the procedure.
Patients with rheumatoid arthritis inevitably suffer from polypharmacy. This patient had previously taken indomethacin in a relatively high dose of 200 mg and had also received feprazone.
Indomethacin has only rarely been reported as a possible cause of thrombocytopenia.5 Feprazone has a pyrazolidine ring in common with phenylbutazone and as such might have the potential for causing thrombocytopenia. But no case of thrombocytopenia has so far been reported with feprazone treatment. It thus appears that levamisole was the likely cause of a low platelet count in this patient.
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Centre There were 53 patients aged 44 to 60, eight of them women. All the patients had been in regular employment. One patient had died from a myocardial infarction shortly after return home and one could not be traced. The progress of the remaining 51 patients is summarised in the figure.
Of the 35 patients who returned to work, the average interval between operation and return to work was 4-5 months. Sixteen patients did not return to work after operation. Of the thirteen who had not worked before operation, ten were men. Of these, four had either myocardial or cerebrovascular problems, one had unrelated malignant disease, two became redundant, and the remainder felt they "just could not manage." Of the three women who did not return, one had developed an upper limb occlusion and the others had been advised to retire by either medical board or spouse, although all three commented on a definite postoperative improvement at the end of the questionnaire, and none complained of difficulties in performing routine housework. Of the remaining three patients who had worked before operation, the first sustained a myocardial infarction, the second a myocardial infarction with a cerebrovascular accident later, and the third was offered early retirement. Working history in relation to aortofemoral bypass.
When judging the success of vascular operations patency rates tend to be quoted and the patient's return to a normal working life forgotten. In this series 29 patients were totally lost to productive employment before operation. Sixteen of these returned to active employment, 14 to their original work, and this was in a region of high unemployment. The current economic climate must naturally invite medical audit and cost-effectiveness studies.1 a Without taking into account any other benefit produced by aortofemoral bypass, we conclude that the operation produces a definite return to employment in those who would otherwise draw permanent sickness benefit.
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